Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NUBEQA vs ANDROGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Treatment of patients with non-metastatic castration-resistant prostate cancer (nm CRPC),Treatment of patients with metastatic hormone-sensitive prostate cancer (m HSPC) in combination with docetaxel
Primary hypogonadism (congenital or acquired),Hypogonadotropic hypogonadism,Off-label: delayed puberty in males, certain breast cancers
600 mg orally twice daily with food.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
Terminal elimination half-life is approximately 20 hours; supports once-daily dosing.
The terminal elimination half-life of testosterone from Andro Gel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
Primarily metabolized by CYP3A4 and also by CYP2C8 and UGT1A1 to a lesser extent.
Hepatic via CYP3A4, CYP2C9, and 17β-hydroxysteroid dehydrogenase; metabolites include estradiol and dihydrotestosterone.
Primarily excreted as unchanged drug via feces (approximately 63.7%) and urine (approximately 23.8%); minimal biliary excretion.
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Approximately 97% bound to plasma proteins (primarily albumin).
Approximately 98% of circulating testosterone is protein-bound: 40-50% bound to sex hormone-binding globulin (SHBG) and 50-60% loosely bound to albumin.
Apparent volume of distribution is approximately 98 L (1.2 L/kg for a 80 kg patient), indicating extensive tissue distribution.
The apparent volume of distribution of testosterone is about 1.0 L/kg, reflecting extensive distribution into tissues, particularly muscle, skin, and male reproductive organs.
Absolute oral bioavailability is approximately 21% (fasted state); increased by 2.6-fold with a high-fat meal.
Bioavailability of testosterone from Andro Gel is approximately 10-14% of the applied dose, due to limited skin permeation and first-pass metabolism (though minimal with transdermal route). For comparison, oral testosterone bioavailability is <1%, while intramuscular testosterone enanthate has 100% bioavailability.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
No specific dose adjustment is provided for renal impairment. Use with caution in patients with severe renal impairment due to potential for fluid retention.
Child-Pugh A: No adjustment. Child-Pugh B: Not recommended. Child-Pugh C: Contraindicated.
Contraindicated in patients with Child-Pugh class C (severe hepatic impairment). Use with caution and monitor liver function in mild to moderate hepatic impairment; no specific dose reduction guidelines exist.
Safety and efficacy not established; no recommended dose.
Not indicated in pediatric patients under 18 years of age; safety and efficacy have not been established.
No dose adjustment required based on age alone; monitor for adverse effects.
Elderly patients may be more sensitive to androgens, and require careful monitoring for prostate enlargement, prostate cancer, and fluid retention. Start at the lowest dose (25 mg daily) and titrate based on serum testosterone levels and clinical response.
None.
None.
Ischemic cardiovascular events,Hypertension,Fractures,Seizures,Posterior reversible encephalopathy syndrome (PRES),Hypersensitivity reactions,Fetal toxicity
Risk of secondary exposure to testosterone (children) – avoid skin contact,Polycythemia (monitor hematocrit),Prostate enlargement/cancer risk,Cardiovascular risk (especially in elderly),Spermatogenesis suppression,Hepatic effects (monitor liver function),Edema (in patients with preexisting conditions)
Pregnancy,Severe hepatic impairment (Child-Pugh C)
Known hypersensitivity to testosterone or gel components,Prostate cancer,Breast cancer (males),Women who are pregnant or may become pregnant (risk to fetus)
Take with food to increase absorption; food with moderate-to-high fat content enhances bioavailability. Avoid grapefruit juice or products containing grapefruit as they may inhibit P-gp and increase darolutamide levels.
No specific food interactions. Grapefruit juice may increase testosterone levels due to CYP3A4 inhibition, but clinical significance is unclear. Avoid excessive alcohol intake as it may affect testosterone levels and liver function.
NUBEQA (darolutamide) is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibition), it can cause fetal harm. Animal studies have shown adverse developmental effects including embryotoxicity and malformations in rats at exposures below human clinical exposure. No adequate human data exist. It should not be used in pregnant women or those planning to become pregnant. If exposure occurs during pregnancy, the patient should be apprised of the potential hazard to the fetus.
Andro Gel (testosterone) is contraindicated in pregnancy. Testosterone is a teratogen with masculinization of female fetuses (clitoral enlargement, labial fusion, urogenital sinus abnormalities) when exposed during the first trimester. Second and third trimester exposure may cause pseudohermaphroditism in females. Risk is highest during the first 12 weeks of gestation.
It is unknown whether darolutamide or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment with NUBEQA and for at least 1 week after the final dose. The milk-to-plasma ratio (M/P ratio) is not available.
Testosterone is excreted into breast milk with an estimated M/P ratio of 0.1-0.3. It may cause virilization in nursing infants. Breastfeeding is not recommended during Andro Gel therapy.
No dosing adjustment recommendations are available for use during pregnancy because NUBEQA is contraindicated in pregnant women. There are no clinical data regarding the pharmacokinetic changes in pregnancy, and no studies have evaluated the need for dose adjustment in this population. Therefore, no specific dose adjustments for pregnancy are provided.
Andro Gel is contraindicated in pregnancy; no dose adjustments are applicable. If exposure occurs, discontinue immediately and monitor for fetal effects.
NUBEQA (darolutamide) is a non-steroidal androgen receptor inhibitor with low blood-brain barrier penetration, reducing CNS side effects like falls and fractures. Monitor for cardiovascular events and hypertension; dose adjustment required in severe renal impairment (e GFR 15-29 m L/min) or moderate hepatic impairment (Child-Pugh B). Administer with food to enhance absorption. No dose adjustment for mild renal or hepatic impairment.
Apply to clean, dry, intact skin on shoulders, upper arms, or abdomen. Avoid application to genitals or chest due to higher absorption and risk of transfer. Wash hands after application. Allow gel to dry before dressing. Monitor serum testosterone, hematocrit, PSA, and lipid profile. Contraindicated in men with breast or prostate cancer. May cause erythrocytosis, sleep apnea, or worsening of BPH. Risk of testosterone transfer to women or children; cover application site or wash skin before contact.
Take NUBEQA with food at the same time each day.,Swallow tablets whole; do not crush, chew, or split.,Do not take with strong P-glycoprotein (P-gp) inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole).,Report unusual bleeding, bruising, or signs of bleeding (e.g., blood in urine or stool).,Use effective contraception during treatment and for 1 week after last dose if partner could become pregnant.,Inform your doctor if you have severe kidney or moderate liver problems.
Apply Andro Gel once daily at the same time each morning to clean, dry, intact skin on shoulders, upper arms, or abdomen.,Do not apply to genitals or chest.,Wash hands thoroughly with soap and water after application.,Allow gel to dry completely before dressing or coming into contact with others.,Avoid swimming, showering, or bathing for at least 5 hours after application.,If skin contact with another person is likely, cover the application site with clothing or wash the area before contact.,Keep Andro Gel away from children and women of childbearing potential.,Report any signs of deep vein thrombosis (leg swelling, pain, warmth), heart attack (chest pain, shortness of breath), or stroke (sudden weakness, confusion, vision changes).,Regular blood tests are required to monitor testosterone levels, red blood cell count, prostate health, and cholesterol.,Andro Gel may interact with blood thinners (e.g., warfarin) and corticosteroids; inform all healthcare providers.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NUBEQA vs ANDROGEL, answered by our medical review team.
NUBEQA is a Androgen Receptor Inhibitor that works by Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.. ANDROGEL is a Androgen that works by Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NUBEQA and ANDROGEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NUBEQA is: 600 mg orally twice daily with food.. The standard adult dose of ANDROGEL is: 50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NUBEQA and ANDROGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NUBEQA is classified as Category C. NUBEQA (darolutamide) is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibition), it can cause fetal harm. Animal studies have shown adverse d. ANDROGEL is classified as Category C. AndroGel (testosterone) is contraindicated in pregnancy. Testosterone is a teratogen with masculinization of female fetuses (clitoral enlargement, labial fusion, urogenital sinus a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.